DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for diabetic retinopathy — screening already-approved drugs against its 41-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDiabetic retinopathy maps to a 41-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside diabetic retinopathy in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of AKR1C3 — Gliclazide has a real, experimentally solved structure in complex with this target (PDB 4ZFC, 2.0 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet gczdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4ZFC · 2.0 Å · ligand Gliclazide (GCZ). Experimental structure, not a prediction.
What the evidence adds up to
The 2007 review describes diabetic retinopathy as a consequence of chronic hyperglycaemia acting through aldose reductase, advanced glycation end products, and protein kinase C pathways to damage retinal capillary endothelial cells. Vision loss results from vascular leakage or ischaemia. Modifiable risk factors include A1C level, hypertension, cigarette smoking, and dyslipidaemia. Tight glucose and blood pressure control reduce risk and progression. Aspirin therapy and smoking cessation are recommended. Laser photocoagulation reduces the risk of vision loss in diabetic macular oedema, severe nonproliferative diabetic retinopathy, or proliferative diabetic retinopathy. Intraocular surgery is used for vitreous haemorrhage and macular retinal detachment. Whether treating dyslipidaemia provides vision benefits remains undetermined.
A 2008 proteomic study of vitreous fluid from 4 diabetic patients with proliferative diabetic retinopathy and 8 non-diabetic controls with macular hole found that intravitreous apolipoprotein A-I and apolipoprotein H levels were significantly higher in the diabetic group. Western blot analysis of 7 additional PDR samples and 7 controls confirmed the elevation. In 7 postmortem diabetic retinas compared with 7 non-diabetic retinas, mRNA levels of both apolipoproteins were significantly higher, with retinal pigment epithelium as the main contributor. The authors suggest these findings may be relevant to new treatment strategies.
A 2019 review notes that diabetic retinopathy remains a major cause of blindness in diabetics, leading to decreased vision, visual field defects, vitreous haemorrhage, traction retinal detachment, and blindness. It reviews progress in laser, drug, and gene treatment but does not report any new drug efficacy data or clinical trial results from repurposed agents. The review does not name any specific drug not already covered in the earlier abstracts.
What is still missing is a randomised controlled trial testing whether raising or lowering apolipoprotein A-I or H in the eye alters retinopathy progression. No such trial has been funded or conducted. The 2007 review’s unanswered question about whether lipid-lowering drugs improve vision outcomes remains unanswered. Patient stratification by apolipoprotein levels or by specific biochemical pathway activation has not been attempted in a clinical setting.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Health-System Pharmacy · 2007 · 71 citations
Screening for and managing diabetic retinopathy: Current approaches
AbstractPURPOSE: The anatomy of the eye and the pathogenesis, clinical features, and prevalence of vision impairment from diabetic retinopathy are described. Screening and risk factors for and treatment of diabetic retinopathy also are addressed. SUMMARY: The macula and fovea play a critical role in vision. Several interrelated biochemical pathways involving aldose reductase, advanced glycation end products, and protein kinase C link chronic hyperglycemia with retinal capillary endothelial cell damage and dysfunction in patients with diabetic retinopathy. Vision loss and blindness from diabetic retinopathy usually are the result of vascular leakage or ischemia. Screening for retinopathy should be performed within three to five years after the onset of type 1 diabetes and shortly after the diagnosis of type 2 disease, with annual follow-up examinations in both types of diabetes. In patients with diabetic retinopathy, severe vision impairment is less common and less readily corrected than mild vision impairment, and vision impairment is more common and less readily corrected in elderly patients with diabetes than in younger diabetics. Modifiable risk factors for diabetic retinopathy include A1C level, hypertension, cigarette smoking, and dyslipidemia. Tight control of blood glucose concentrations and blood pressure can reduce the risk for and progression of diabetic retinopathy. Aspirin therapy and smoking cessation also are recommended. Dyslipidemia in patients with diabetes is associated with retinopathy progression and vision loss. Treatment of dyslipidemia provides cardiovascular benefits in patients with diabetes, but whether it provides vision benefits remains to be determined. Laser photocoagulation therapy reduces the risk of vision loss in patients with diabetic macular edema, severe nonproliferative diabetic retinopathy, or proliferative diabetic retinopathy. Intraocular surgery may be used for patients with vitreous hemorrhage and retinal detachment of the macula. CONCLUSION: Therapeutic approaches used for patients with or at risk for diabetic retinopathy include drug therapy to reduce modifiable risk factors, laser photocoagulation, and intraocular surgery. Screening plays an important role in early detection and intervention to prevent the progression of diabetic retinopathy.
Elevation of Apolipoprotein A-I and Apolipoprotein H Levels in the Vitreous Fluid and Overexpression in the Retina of Diabetic Patients
AbstractOBJECTIVES: To determine levels of apolipoprotein (apo) A-I and apo H in the vitreous fluid of patients with proliferative diabetic retinopathy (PDR) and to examine whether apo A-I and apo H messenger RNA (mRNA) levels are overexpressed in the diabetic retina. METHODS: Vitreous samples from 4 diabetic patients with PDR and 8 nondiabetic patients with macular hole were selected for proteomic analysis. Fourteen additional samples (7 from patients with PDR and 7 from patients with macular hole) were used for Western blot analysis. Fourteen postmortem eyes (7 from diabetic and 7 from nondiabetic donors) were used to perform quantitative real-time polymerase chain reaction analysis. RESULTS: Intravitreous apo A-I and apo H levels were significantly higher in patients with PDR than in the control group. The apo A-I and apo H mRNA levels obtained from the retinas of diabetic donors were significantly higher than those obtained from nondiabetic donors. Retinal pigment epithelium was the main contributor to the differences. CONCLUSIONS: Levels of apo A-I and apo H are elevated in the vitreous fluid of diabetic patients with PDR. In addition, we provide the first evidence, to our knowledge, that a higher expression of apo A-I and apo H mRNAs exists in the diabetic retina. CLINICAL RELEVANCE: The results of this study may be relevant to new treatment strategies aimed toward reducing the development of diabetic retinopathy.
The Tohoku Journal of Experimental Medicine · 1983 · 7 citations · open access
Preventive and therapeutic effects of gliclazide on diabetic retinopathy: Comparison with glibenclamide treatment.
AbstractThe effects of long-term treatment with gliclazide on diabetic retinopathy and platelet adhesion were investigated. The subjects comprised 25 patients with NIDDM, of which 12 cases and 13 cases were treated with gliclazide and glibenclamide respectively. An improvement in retinopathy was observed in 7 out of 12 cases in the gliclazide-treated group. Of the remaining 5 cases, four cases remained unchanged and one deteriorated. Of the 13 cases treated with glibenclamide, on the other hand, only two cases showed an improvement in retinopathy after treatment, 7 cases remained unchanged and 4 cases deteriorated. The values for the platelet adhesion test following 3 years treatment were 52 +/- 14% and 42 +/- 17% in the gliclazide and the glibenclamide-treated groups respectively. These results were not statistically significant. These data indicate that gliclazide might be more effective than glibenclamide with respect to either improving diabetic retinopathy or preventing its progression.
DOAJ (DOAJ: Directory of Open Access Journals) · 2019 · 2 citations · open access
New progress in clinical treatment of diabetic retinopathy
AbstractDiabetic retinopathy is one of the serious complications of diabetes, which often results in decreased vision, visual field defects, vitreous hemorrhage,even traction retinal detachment, and blindness in the end. The disease is a major cause of blindness in diabetics, which seriously affects the quality of patients' life. This article reviews new progress in laser, drug and gene treatment of diabetic retinopathy.
AbstractRetinopathy is a common complication of diabetes that can lead to enormous personal and economic sequelae. Interventions that address the risk factors for developing retinopathy, such as tight glycaemic control, blood pressure control and lowering of lipids, and early identification of any problems, through the national screening programme, can help to limit the damaging effects of diabetic retinopathy. Available treatments include laser photocoagulation, vitrectomy and intravitreally injected steroids and anti-vascular endothelial growth factor which can halt the progress of neovascularizaton.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
